Apollo Hospitals Enterprise, India’s largest hospital chain by revenue, is accelerating preparations to take its omni-channel healthcare subsidiary Apollo HealthCo public by the fourth quarter of FY27. A series of strategic moves—including restructuring, margin expansion, capacity additions, and consolidation of subsidiaries—signals the group’s ambition to unlock value in a rapidly formalising healthcare market.
Senior executives across multiple investor interactions have highlighted that HealthCo is on track to become an INR 25,000-crore revenue engine, delivering 6–7% EBITDA margins by FY27, backed by improving profitability, digital scale-up, and operational efficiencies.
Apollo HealthCo IPO: From Turnaround to Public Debut
Apollo HealthCo combines:
- Offline pharmacy distribution
- Apollo 24/7 digital health platform
- Keimed, soon to be merged for deeper backend synergies
The business has undergone a sharp turnaround over the past year.
Key performance highlights:
- PAT jumped fourfold to INR 73.4 crore in Q2 FY26
- Cash losses reduced by over 50% YoY, from INR 85 crore to INR 38.6 crore
- Current EBITDA margin: 4.4%, driven primarily by pharmacies
- Offline pharmacy EBITDA margin: 7.8%
- Digital health services: still loss-making, but expected to break even within two quarters
CFO Krishnan Akhileswaran reiterated confidence in the company’s run-rate at listing:
“By the time HealthCo lists in Q4 FY27, it will be run-rating at INR 25,000 crore with 6–7% EBITDA margins. Operational efficiencies, same-store growth, and private label expansion will drive this shift.”
Importantly, the group secured Competition Commission of India (CCI) approval for the restructuring of Apollo HealthCo, Keimed, and Apollo Healthtech, enabling streamlined governance and unlocking potential synergies.
AHLL Consolidation: Strategic Buyback & Strong Growth
Apollo Hospitals is simultaneously strengthening its retail and speciality healthcare arm—Apollo Health & Lifestyle (AHLL)—by buying back the stake held by IFC in an INR 2,000 crore all-cash transaction, fully funded by internal accruals.
AHLL includes:
- Diagnostics
- Clinics
- Specialty centers
- Corporate outreach initiatives
The business continues to deliver robust performance:
- 17% revenue growth in Q2 FY26
- 21% EBITDA growth
- Increasing contribution from diagnostics, a high-margin vertical
Akhileswaran emphasised that no external capital raise is planned for AHLL despite investor interest, underscoring AHEL’s solid balance sheet and annual internal accrual generation of INR 1,500 crore.
Massive INR 8,300 Cr Expansion: 4,400+ New Beds Planned
Apollo is doubling down on physical healthcare infrastructure with one of its largest expansion cycles to date. Across all reports, the contours of the plan are consistent:
- Total investment: INR 8,300 crore
- Beds to be added: 3,650–4,400 (spread across different disclosures)
- Time horizon: FY30, with major projects coming online in the next 18 months
- INR 5,800 crore yet to be deployed
The mix includes greenfield as well as brownfield expansions across major Indian metros:
- Pune
- Hyderabad
- Kolkata
- Chennai
- Mumbai
- Delhi
- Gurgaon
- Bengaluru
Apollo currently operates around 10,000 beds and is preparing to cross 13,000+ beds as part of this expansion cycle. COO and senior leadership note that new hospitals are delivering 15–17% IRR, reflecting disciplined capital allocation and strong patient demand.
Additionally, the group observes rising inflows from international patients, especially from:
- Bangladesh
- Middle East
Financials: Consistent, Broad-Based Growth
Across the September quarter and half-yearly reports (Q2 FY25 & Q2 FY26 data in different sources), Apollo continues to show strong operational momentum.
Q2 FY26 Key Figures:
- Revenue (Q2): INR 6,304 crore, up 13%
- EBITDA: INR 941 crore, up 15%
- Net profit: INR 477 crore, up 26%
H1 FY26 Performance:
- Revenue: INR 12,146 crore, up 14%
- PAT: INR 910 crore, up 33%
Segmental highlights:
- Healthcare services: 9% YoY growth
- Diagnostics & retail healthcare (AHLL): 17% growth
- Digital + pharmacy (HealthCo): 17% growth
- Hospital division EBITDA margin: ~24.6%
- Group PAT growth: 33% YoY (H1 FY26)
Occupancy levels stand at 69%, leaving room for further throughput gains even before capacity expansion comes online.
Strategic Importance: Why This Matters for Investors
AHEL’s multi-pronged strategy is aimed at strengthening its position as India’s undisputed integrated healthcare leader.
1. Apollo HealthCo IPO Unlocks Value
The digital + pharmacy arm has historically weighed on consolidated margins. Carving out HealthCo creates:
- Better valuation discovery
- Potential for fresh strategic partnerships
- A clearer capital structure
- Reduced drag on hospital margins
2. Bed Expansion Boosts Core Profitability
Hospitals remain the cash engine with 24–25% EBITDA margins and rising occupancies. New beds and metro-focused projects enhance:
- Revenue visibility
- Operational leverage
- High IRR returns
3. Diagnostics & Outpatient Growth
AHLL’s expansion and high-margin diagnostics segment continue to scale rapidly—an attractive counterbalance to capital-intensive hospitals.
4. Strong Fundamentals
The group’s financial strength—backed fully by internal accruals—enables aggressive expansion without stretching leverage.
Outlook
Apollo Hospitals is entering FY26–FY30 with a uniquely synchronised growth strategy: a high-visibility IPO, a robust expansion pipeline, differentiated digital assets, and improving profitability across retail healthcare, diagnostics, and pharmacies.
If execution holds, Apollo HealthCo IPO listing could emerge as one of India’s most significant healthcare IPOs of the decade, potentially reshaping valuation benchmarks for integrated healthcare businesses.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.